BC Innovations | Dec 13, 2016
Distillery Therapeutics

Inflammation

INDICATION: Asthma Cell culture and mouse studies suggest CHRNA7 agonists could help treat allergic asthma. In a mouse model of airway hyperresponsiveness, intranasal administration of a CHRNA7 agonist tool compound decreased airway resistance and dynamic...
BC Innovations | Mar 10, 2016
Distillery Therapeutics

Therapeutics: Nicotinic acetylcholine receptor α7 (CHRNA7)

Inflammation INDICATION: Shock / trauma Rat and mouse studies suggest agonizing CHRNA7 could help treat traumatic brain injury (TBI) by decreasing damage to the blood-brain barrier (BBB). In a rat model of TBI, a CHRNA7...
BC Innovations | Dec 3, 2015
Distillery Therapeutics

Therapeutics: Nicotinic acetylcholine receptor α7 (CHRNA7)

Autoimmune disease INDICATION: Inflammatory bowel disease (IBD) Mouse studies suggest CHRNA7 partial agonists could help treat ulcerative colitis (UC). In a mouse model of chemical-induced UC, encenicline, a partial agonist of CHRNA7, decreased intestinal inflammation,...
BioCentury | Sep 14, 2015
Strategy

Mind melding

Novartis AG's third neuroscience deal of the summer checks two boxes for the pharma by sharing the risk for a BACE inhibitor program and adding another late-stage program in neurology, all without increasing the pharma's...
BC Week In Review | Jan 5, 2015
Company News

Novartis, Vanda deal

Vanda regained exclusive U.S. and Canadian rights from Novartis to Fanapt iloperidone. The deal settled a licensing dispute between the two companies in which Vanda had begun an arbitration proceeding in May seeking $539 million...
BC Extra | Dec 24, 2014
Company News

Vanda climbs on Fanapt settlement

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) rose $1.67 (14%) to $13.58 on Tuesday after it reacquired exclusive U.S. and Canadian rights to Fanapt iloperidone from Novartis AG (NYSE:NVS; SIX:NOVN). The deal settled a licensing dispute between the...
Items per page:
1 - 6 of 6